Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.

Continuar

Regresar

Are you prescribing in line with treatment guidelines for your mild to moderate inflammatory acne patients?

Go to Close Top

Web

EDF S3-Guideline for the treatment of acne (Updated 2016):

  • Highest recommendation for fixed-dose combinations of Benzoyl Peroxide (BPO) + clindamycin (Duac) or BPO + adapalene as first-line therapy for the treatment of mild to moderate papulopustular acne 1
  • Recommends against the use of topical antibiotic monotherapies to reduce the development of antibiotic resistance 1

Find out more

Web

AAD Guidelines of care for the management of acne vulgaris (Updated 2016):

  • Recommend combinations of topical antibiotics and benzoyl peroxide as a first line therapy in mild to moderate acne patients (Class A recommendation, Level I evidence) 2
  • Recommend against the use of topical antibiotic monotherapies to reduce the development of antibiotic resistance 2

Find out more

References:

  1. Nast A et al. JEADV 2016;30(8):1261–1268.
  2. Zaenglein AL et al. J Am Acad Dermatol 2016;74(5):945–973.e33.

Duac is a registered trademark of Stiefel, a GSK company.